A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients

Completed · Phase 2 · Has a placebo group

Conditions studied: Alzheimer Disease

In brief

A 10-week safety and tolerability study of a potential treatment for mild to moderate Alzheimer's disease.

Key facts

Study ID: NCT00141661
Run by: Pfizer
People needed: 67
Starts: 2005-10-01
Expected to finish: 2006-06-01
Last updated by the study team: 2009-08-20

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Diagnosis of probably Alzheimer's disease for at least 1 year.
Mini Mental State Exam (MMSE) score between 12-26 at screening.
Participants must be receiving a cholinesterase inhibitor and/or memantine for at least 4 months, and on a stable dose for at least 2 months.

You may not qualify if…

Current evidence of a neurological or psychiatric illness that could contribute to dementia.
Living alone.
Poorly controlled high blood pressure.

Where it is running

Pfizer Investigational Site — Sun City, Arizona, United States
Pfizer Investigational Site — Fresno, California, United States
Pfizer Investigational Site — San Diego, California, United States
Pfizer Investigational Site — San Francisco, California, United States
Pfizer Investigational Site — Fort Lauderdale, Florida, United States
Pfizer Investigational Site — Fort Myers, Florida, United States
Pfizer Investigational Site — Hallandale, Florida, United States
Pfizer Investigational Site — Jacksonville, Florida, United States
Pfizer Investigational Site — Largo, Florida, United States
Pfizer Investigational Site — Orlando, Florida, United States
Pfizer Investigational Site — West Palm Beach, Florida, United States
Pfizer Investigational Site — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.